FDA | Page 2

The controversy over genetic-testing company 23andMe begs the question: Is knowledge really that dangerous?

The FDA's decision to phase out trans fats has been met with little resistance, due to easy substitutes and consensus on the ingredient's unhealthiness.

Until now, the the Food & Drug Administration has taken a largely hands-off approach to medical apps. For those entrepreneurs who are subject to FDA scrutiny, however, the process can be daunting.